Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective
Executive Summary
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.
You may also be interested in...
FDA Expands Indication For Axonics’ Incontinence System; Medtronic Claims Patent Infringement
The US FDA approved Axonics’ r-SNM sacral neuromodulation system for treating overactive bladder and urinary retention on 14 November. The agency approved the same device for treating chronic fecal incontinence on 9 September. Axonics expects r-SNM to rival Medtronic's InterStim II non-rechargeable sacral neuromodulation system, but Medtronic claims the r-SNM technology infringes on Medtronic’s intellectual property.
Seventeen And Counting – Bumper Crop Of New EU Filings
Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.
ViiV & Janssen Win English Funding First For HIV Therapy
Around 13,000 people are now expected to be eligible for treatment with the long-acting, injectable Vocabria/Rekambys combination therapy in England.